Interim Healthcare

Item 7 outlines an initial investment of $156,000-$239,000, including a $75,000 franchise fee, with ongoing fees featuring tiered royalties from 3.25% to 5.5% based on payer type, 1% ad fund, and a $485 monthly technology fee—these are moderately competitive for healthcare services but the tech add-on bumps total costs. No Item 19 means no disclosed earnings, forcing reliance on broader metrics like 56 SBA loans averaging $392,716 with a 10.7% default rate, which is below average for franchises but signals some financing risks amid rising healthcare demands. For a $200K-ish outlay, operators target facilities and in-home care, but the tiered structure could squeeze margins on lower-payer contracts.

The system contracted 3% from 234 to 226 locations between 2023-2024, with 13 terminations, 1 non-renewal, and 4 transfers signaling moderate instability versus healthcare peers growing briskly. Litigation flags in the FDD highlight breaches like non-compete violations, royalty disputes, and ownership transfer issues, pointing to enforcement tensions that could complicate exits or expansions. Exclusive territories help, but without revenue transparency and amid contraction, this feels riskier for newcomers—veterans in healthcare might navigate it, but data urges caution on scaling in a payer-sensitive model.